glp-1/gip dual agonist weight loss TrimRX Frontiers | GLP-1/GIP dual agonist
Description
Allan KC, et al
Hompesch, S
This in turn reduces the amount of insulin the body needs, ultimately resulting in reduced hyperglycemia and improved control of glucose levels
For broader regulatory context, see FDA Peptide Reclassification 2026: What It Means for Canadian Researchers
Between 2019 and December 2023 there has been a greater than 932% increase in prescriptions for semaglutide medications
IIH is driven by an increase in intracranial pressure that can present as severe visual loss to debilitating headaches due to compression of the optic nerve and papilloedema [101]
